Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0256)
| Name |
Nitidine chloride
|
||||
|---|---|---|---|---|---|
| Synonyms |
Nitidine chloride; 13063-04-2; Nitidine (chloride); 2,3-Dimethoxy-12-methyl-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]phenanthridin-12-ium chloride; Nitidine, chloride; NSC146397; NSC-146397; XO8WQL69T8; 13063-04-2 (CHLORIDE); (1,3)-BENZODIOXOLO(5,6-c)PHENANTHRIDINIUM, 2,3-DIMETHOXY-12-METHYL-, CHLORIDE; NSC 146397; 2,3-Dimethoxy-12-methyl-(1,3)-benzodioxolo(5,6-c)phenanthridinium chloride; Nitidinechloride; 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride; angolinine; Nitidine-Chloride; UNII-XO8WQL69T8; CHEMBL8443; SCHEMBL420918; DTXSID50926842; HY-N0498; MFCD01659688; AKOS016003480; CCG-268448; 2,3-Dimethoxy-12-methyl-[1,3]dioxolo[4',5':4,5]-benzo[1,2-c]phenanthridin-12-ium chloride; AS-73875; CS-0009022; FT-0689357; A14701; A909300; Q-100120; Q-100770; WLN: T G6 D6 C665 EK SO UO THJ E1 IO1 JO1 &G; [1,6-c]phenanthridinium, 2,3-dimethoxy-12-methyl-, chloride; [1,3]Benzodioxolo[5,6-c]phenanthridinium, 2,3-dimethoxy-12-methyl-, chloride (1:1); 1,3)BENZODIOXOLO(5,6-C)PHENANTHRIDINIUM, 2,3-DIMETHOXY-12-METHYL-, CHLORIDE (1:1); 2,3-Dimethoxy-12-methyl-9H-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium chloride; 16,17-DIMETHOXY-21-METHYL-5,7-DIOXA-21-AZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(1)?]HENICOSA-1(13),2(10),3,8,11,14(19),15,17,20-NONAEN-21-IUM CHLORIDE
Click to Show/Hide
|
||||
| Status |
Investigative
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C21H18ClNO4
|
||||
| IUPAC Name |
2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride
|
||||
| Canonical SMILES |
C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-]
|
||||
| InChI |
InChI=1S/C21H18NO4.ClH/c1-22-10-13-7-17(23-2)18(24-3)8-15(13)14-5-4-12-6-19-20(26-11-25-19)9-16(12)21(14)22;/h4-10H,11H2,1-3H3;1H/q+1;/p-1
|
||||
| InChIKey |
QLDAACVSUMUMOR-UHFFFAOYSA-M
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Responsed Disease | Multiple myeloma | ICD-11: 2A83 | |||
| Responsed Regulator | ATP-binding cassette sub-family B member 6 (ABCB6) | Suppressor | |||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | |||
| Fatty acid metabolism | hsa01212 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | U266B1 cells | Plasma cell myeloma | Homo sapiens | CVCL_0566 | |
| RPMI-8226 cells | Plasma cell myeloma | Homo sapiens | CVCL_0014 | ||
| Sp2/0-Ag14 cells | Plasma cell myeloma | Mus musculus | CVCL_2199 | ||
| In Vivo Model |
Male BALB/c nude mice, aged 5 weeks, were procured from Guangzhou Ruige biology Model Animal Research Center (No. 44827200001656, Guangzhou, China). Tumor xenograft assay was performed by dissolving SP2/0 cells in PBS (1 x 106/200 uL) and subcutaneously inoculating them into the right flank of mice. After the tumor reached 50 mm3, the tumor-bearing mice were randomly separated into three groups and intraperitoneally administered with NC (4.6 or 6 mg/kg) every two days. Body masses and tumor sizes were determined every day. Subsequently, the mice were sacrificed, and the inhibition of tumor growth and the tumor masses were determined. Later, visceral organs and tumors from every group were harvested and immobilized in paraformaldehyde (4%). All murine experimental procedures conformed to the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Click to Show/Hide
|
||||
| Response regulation | Mechanistically, the direct binding of Nitidine chloride (NC) to ABCB6 suppressed PI3K/AKT signaling pathway to promote ferroptosis. In conclusion, ABCB6 can be a potential therapeutic target and prognostic biomarker in Multiple myeloma (MM), while NC can be considered a novel drug for MM treatment. | ||||